Increased MARCKS Activity in BRAF Inhibitor-Resistant Melanoma Cells Is Essential for Their Enhanced Metastatic Behavior Independent of Elevated WNT5A and IL-6 Signaling

SIMPLE SUMMARY: Approximately 60% of all melanoma patients have cancer with an activating BRAF mutation that can be effectively treated with a BRAF inhibitor. Unfortunately, such treatment often leads to rapid development of BRAF inhibitor-resistance. These BRAF inhibitor-resistant melanomas are als...

Descripción completa

Detalles Bibliográficos
Autores principales: Yadav, Vikas, Jobe, Njainday, Satapathy, Shakti Ranjan, Mohapatra, Purusottam, Andersson, Tommy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775662/
https://www.ncbi.nlm.nih.gov/pubmed/36551563
http://dx.doi.org/10.3390/cancers14246077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775662/
https://www.ncbi.nlm.nih.gov/pubmed/36551563
http://dx.doi.org/10.3390/cancers14246077

Ejemplares similares